Financing boom for German biotechs

The sector was able to raise around 2.3 billion euros last year. That is almost a record.

German biotechs were able to raise a total of 2.3 billion euros last year. 2021 was therefore the second strongest year in history for biotechs in Germany, according to the BIO Deutschland association. More investments were only made in the record year of 2020, when investors invested around three billion euros.

Private biotechs were able to raise around 851 million euros in venture capital. Public companies in the sector raised capital of around 748 million euros. Particularly striking was the therapy developer Emergence Therapeutics, which received 87 million euros in a Series A financing round.

Oliver Schacht, CEO of BIO Deutschland, explains that although the financing situation in the German biotech sector is developing positively, there is still a lot of room for improvement in order to develop Germany into a leading location for biotechnology. "The traffic light government should now make biotechnology a top priority so that we can soon tell even more success stories, not only in the field of health, but also in combating climate change and in sustainable bio-based production, the circular economy and nutrition," says Schacht.